Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): A new BC-specific prognostic model and a nomogram

Neuro-Oncology

Volumn 14, Issue 8, 2012, Pages 1105-1113

  Ahn, Hee Kyung ^a   Lee, Soohyeon ^a,d   Park, Yeon Hee ^a   Sohn, Joo Hyuk ^d   Jo, Jae Cheol ^e   Ahn, Jin Hee ^e   Jung, Kyung Hae ^e   Park, Silvia ^a   Cho, Eun Yoon ^b   Lee, Jung Il ^b   Park, Won ^c   Choi, Doo Ho ^c   Huh, Seung Jae ^c   Ahn, Jin Seok ^a   Kim, Sung Bae ^a,e   Im, Young Hyuck ^a  

^a Samsung Medical Center   (South Korea)

^b Department of Pathology ^*  (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

Author keywords

brain metastasis; breast cancer; HER2; prognosis; trastuzumab

Indexed keywords

TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN PARENCHYMA METASTASIS; BREAST CANCER; CANCER CONTROL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GRADED PROGNOSTIC ASSESSMENT; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; NOMOGRAM; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL TIME; VALIDATION PROCESS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NOMOGRAMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; TREATMENT OUTCOME;

EID: 84864683952     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos137     Document Type: Article

References (29)

1. Santarelli JG, Sarkissian V, Hou LC, Veeravagu A, Tse V. Molecular events of brain metastasis. Neurosurg Focus. 2007;22:E1.
2. Al-Shamy G, Sawaya R. Management of brain metastases: The indispensable role of surgery. J Neurooncol. 2009;92:275-282.
3. Tsukada Y, Fouad A, Pickren JW, LaneWW. Central nervous systemmetastasis from breast carcinoma. Autopsy study. Cancer. 1983;52:2349-2354.
4. Lee SS, Ahn JH, KimMK, et al. Brain metastases in breast cancer: Prognostic factors andmanagement. Breast Cancer Res Treat. 2008;111:523-530.
5. Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases: Differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2010;21:942-948.
6. Altundag K, Bondy ML, Mirza NQ, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007;110: 2640-2647.
7. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-751.
8. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70:510-514.
9. Weltman E, Salvajoli JV, Brandt RA, et al. Radiosurgery for brain metastases: A score index for predicting prognosis. Int J Radiat Oncol Biol Phys. 2000;46:1155-1161.
10. Lorenzoni J, Devriendt D, Massager N, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys. 2004;60:218-224.
11. Uhm JE, Park YH, Yi SY, et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum- containing chemotherapy. Int J Cancer. 2009;124:1457-1462.
12. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77:655-661.
13. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271-3277.
14. Lorger M, Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol. 2010;176:2958-2971.
15. Fidler IJ, Balasubramanian K, Lin Q, Kim SW, Kim SJ. The brain microenvironment and cancer metastasis. Mol Cells. 2010;30:93-98.
16. Hinton CV, Avraham S, Avraham HK. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis. 2010;27:97-105.
17. Sperduto PW, Kased N, Roberge D, et al. Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. Int J Radiat Oncol Biol Phys. 2011;82:2111-2117.
18. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol. 2010;28:92-98.
19. Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B, et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat. 2009;117:297-303.
20. Stemmler HJ, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: A treatment challenge. Oncologist. 2008;13:739-750.
21. Park YH, Park MJ, Ji SH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer. 2009;100:894-900.
22. Vogelbaum MA, Suh JH. Resectable brain metastases. J Clin Oncol. 2006;24:1289-1294.
23. Bravo Marques JM. Treatment of brain metastases in patients with HER2+ breast cancer. Adv Ther. 2009;26(suppl 1):S18-S26.
24. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
25. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678-5685.
26. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;359:2814-2823.
27. Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005-1009.
28. Pagani O, Price KN, Gelber RD, et al. Patterns of recurrence of early breast cancer according to estrogen receptor status: A therapeutic target for a quarter of a century. Breast Cancer Res Treat. 2009; 117:319-324.
29. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419-425.